Singular Genomics Systems, Inc.2024财年第三财季实现净利润-16.80百万美元，同比增加24.87%

市场透视11-14

11月14日，Singular Genomics Systems, Inc.（OMIC.US）公布财报，公告显示公司2024财年第三财季净利润为-16.80百万美元，同比增加24.87%；其中营业收入为406000.00美元，同比减少12.12%，每股基本收益为-6.72美元。从资产负债表来看，Singular Genomics Systems, Inc.（OMIC.US）总负债63.30百万美元...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2483681350?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-14 13:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2483681350","market":"us","top_or_hot":-1,"title":"Singular Genomics Systems, Inc.2024财年第三财季实现净利润-16.80百万美元，同比增加24.87%","media":"市场透视","content":"<div>\n<p>11月14日，Singular Genomics Systems, Inc.（OMIC.US）公布财报，公告显示公司2024财年第三财季净利润为-16.80百万美元，同比增加24.87%；其中营业收入为406000.00美元，同比减少12.12%，每股基本收益为-6.72美元。从资产负债表来看，Singular Genomics Systems, Inc.（OMIC.US）总负债63.30百万美元...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114130022a2360fa1&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singular Genomics Systems, Inc.2024财年第三财季实现净利润-16.80百万美元，同比增加24.87%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingular Genomics Systems, Inc.2024财年第三财季实现净利润-16.80百万美元，同比增加24.87%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-14 13:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114130022a2360fa1&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月14日，Singular Genomics Systems, Inc.（OMIC.US）公布财报，公告显示公司2024财年第三财季净利润为-16.80百万美元，同比增加24.87%；其中营业收入为406000.00美元，同比减少12.12%，每股基本收益为-6.72美元。从资产负债表来看，Singular Genomics Systems, Inc.（OMIC.US）总负债63.30百万美元...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114130022a2360fa1&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OMIC","symbol_name":"Singular Genomics Systems Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114130022a2360fa1&s=b","article_id":"2483681350","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114130022a2360fa1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2483681350","pubTimestamp":1731560419,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月14日，Singular Genomics Systems, Inc.公布财报，公告显示公司2024财年第三财季净利润为-16.80百万美元，同比增加24.87%；其中营业收入为406000.00美元，同比减少12.12%，每股基本收益为-6.72美元。从资产负债表来看，Singular Genomics Systems, Inc.总负债63.30百万美元，其中短期债务10.64百万美元，资产负债比为0.03，流动比率为0.08。机构评级：截至2024年11月14日，当前有1家机构对Singular Genomics Systems, Inc.目标价做出预测，其中目标均价为6.50美元，其中最低目标价为6.50美元，最高目标价为6.50美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"OMIC":"Singular Genomics Systems Inc."},"translate_title":"Singular Genomics Systems, Inc. achieved net profit of-US $16.80 million in the third fiscal quarter of fiscal 2024, a year-on-year increase of 24.87%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMIC":1},"content_text":"11月14日，Singular Genomics Systems, Inc.（OMIC.US）公布财报，公告显示公司2024财年第三财季净利润为-16.80百万美元，同比增加24.87%；其中营业收入为406000.00美元，同比减少12.12%，每股基本收益为-6.72美元。从资产负债表来看，Singular Genomics Systems, Inc.（OMIC.US）总负债63.30百万美元，其中短期债务10.64百万美元，资产负债比为0.03，流动比率为0.08。机构评级：截至2024年11月14日，当前有1家机构对Singular Genomics Systems, Inc.目标价做出预测，其中目标均价为6.50美元，其中最低目标价为6.50美元，最高目标价为6.50美元。公司简介：Singular Genomics Systems Inc 是一家生命科学技术公司，利用新型的下一代测序和多组学技术来构建可为研究人员和临床医生提供支持的产品。 产品开发管道包括两个初始集成解决方案，每个解决方案都旨在利用 Sequencing Engine 并专门为解决不同的应用程序而构建。 G4 测序平台旨在瞄准 NGS 市场。 PX Integrated Solution 旨在瞄准单细胞、空间分析和蛋白质组学市场。 这两种集成解决方案都用于许多不同和多样化的细分市场，包括基础生物学、肿瘤学、免疫学、神经学、遗传病、传染病、人类微生物组等等。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483681350"}